Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Public ClinicalTrials.gov record NCT06121180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Study identification
- NCT ID
- NCT06121180
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2024
- Primary completion
- Oct 30, 2030
- Completion
- Oct 30, 2030
- Last update posted
- Dec 3, 2025
2024 – 2030
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Recruiting |
| Northwell Health Center for Advanced Medicine | New Hyde Park | New York | 11042 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Metastatic Uveal Melanoma trials
Other public records listing Metastatic Uveal Melanoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07636785: A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors Not yet recruiting
- NCT04728633: Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Active, not recruiting
- NCT03025256: Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Recruiting
- NCT01587352: Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Active, not recruiting
- NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Active, not recruiting
- NCT06581406: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06121180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06121180 live on ClinicalTrials.gov.